Nexvet Biopharma ($NVET) announced on Monday that it has initiated a pilot trial of NV-02, its anti-nerve growth factor monoclonal antibody to treat pain from osteoarthritis in cats. The trial, which comes close on the heels of Nexvet's positive proof-of-concept efficacy study of the drug, will enroll 90 cats at 15 veterinary sites in the U.S. CEO Mark Heffernan said in a press release the study will help the company determine the optimum dosing regimen for a future pivotal trial. Nexvet believes this is the most advanced clinical trial of any monoclonal antibody designed for cats, and the company hopes to release data in the second quarter of 2016. Release